Université Paris Sorbonne
16 papers found
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)Upload
Missing publications? Search for publications with a matching author name.